Beneficient Cuts Costs 6.5% YoY, Raises $50M, Faces CEO Trial Over $120M Debt
Beneficient regained Nasdaq compliance, cut adjusted operating expenses 6.5% YoY, raised $50 million and reduced $27.5 million of debt. Investments fell to $206 million from $291 million and BEN Liquidity lost $29.2 million, with a former CEO trial over $120 million debt starting April 6, 2026.
1. Governance and Financing Progress
Beneficient reported regaining full Nasdaq listing compliance as of fiscal Q3 and closed a $3 million GP Primary Commitment Financing in December, signaling renewed market interest. The company cut adjusted operating expenses by 6.5% year-over-year (18% YTD excluding non-recurring items) and generated $50 million from asset sales and equity redemptions to pay down $27.5 million of debt.
2. Portfolio Performance and Financial Results
Net investments fell to $206 million from $291 million year-over-year, reflecting limited new financings beyond the December transaction. BEN Liquidity recorded a $29.2 million operating loss in Q3 (YTD loss $36.0 million) with cash at $7.9 million; GAAP revenue was $18.7 million, while adjusted revenue excluding a $44.1 million fair-value gain was negative $25.4 million.
3. Legal Proceedings and Debt Dispute
Management disclosed the former CEO’s criminal trial will commence April 6, 2026, expected to last three to four weeks. Beneficient plans to challenge approximately $120 million of debt tied to entities related to the former CEO, which represents the majority of the company’s $100.3 million total debt.